Treatment of multiple sclerosis (MS)
The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing/remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing/remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing/remitting disease as seen with multiple sclerosis.
1. A method of treating a subject suffering from multiple sclerosis (MS) and presenting clinical signs of MS exacerbations, said method comprising:
administering to the subject an isolated peptide consisting of LQGV (SEQ ID NO: 1) in an amount effective to decrease NFκB-mediated pro-inflammatory cytokine release, so as to treat the subject suffering from multiple sclerosis and presenting clinical signs of MS exacerbations.